BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15183538)

  • 1. Protein levels of alpha1-tubulin, protein disulfide isomerase, tropomyosins and vimentin are regulated by the tuberous sclerosis gene products.
    Hengstschläger M; Rosner M; Fountoulakis M; Oh JE; Lubec G
    Cancer Lett; 2004 Jul; 210(2):219-26. PubMed ID: 15183538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberous sclerosis genes regulate cellular 14-3-3 protein levels.
    Hengstschläger M; Rosner M; Fountoulakis M; Lubec G
    Biochem Biophys Res Commun; 2003 Dec; 312(3):676-83. PubMed ID: 14680818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cellular response to ectopic overexpression of the tuberous sclerosis genes, TSC1 and TSC2: a proteomic approach.
    Hengstschläger M; Rosner M; Fountoulakis M; Lubec G
    Int J Oncol; 2005 Sep; 27(3):831-8. PubMed ID: 16077935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tuberous sclerosis genes, TSC1 and TSC2, trigger different gene expression responses.
    Rosner M; Freilinger A; Lubec G; Hengstschläger M
    Int J Oncol; 2005 Nov; 27(5):1411-24. PubMed ID: 16211238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role of the tuberous sclerosis gene-2 product during neuronal differentiation.
    Soucek T; Hölzl G; Bernaschek G; Hengstschläger M
    Oncogene; 1998 Apr; 16(17):2197-204. PubMed ID: 9619828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteins interacting with the tuberous sclerosis gene products.
    Rosner M; Freilinger A; Hengstschläger M
    Amino Acids; 2004 Oct; 27(2):119-28. PubMed ID: 15351877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense suppression of TSC1 gene product, hamartin, enhances neurite outgrowth in NGF-treated PC12h cells.
    Floricel F; Higaki K; Maki H; Nanba E; Ninomiya H; Ohno K
    Brain Dev; 2007 Sep; 29(8):502-9. PubMed ID: 17376623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal giant cells in the cerebral lesions of tuberous sclerosis complex.
    Mizuguchi M
    Congenit Anom (Kyoto); 2007 Mar; 47(1):2-8. PubMed ID: 17300684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression.
    Soucek T; Rosner M; Miloloza A; Kubista M; Cheadle JP; Sampson JR; Hengstschläger M
    Oncogene; 2001 Aug; 20(35):4904-9. PubMed ID: 11521203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27.
    Rosner M; Freilinger A; Hengstschläger M
    Mutat Res; 2006 Sep; 613(1):10-6. PubMed ID: 16713332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cell cycle and tuberous sclerosis.
    Hengstschläger M; Rosner M
    Prog Cell Cycle Res; 2003; 5():43-8. PubMed ID: 14593699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
    Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
    Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of PCNA and CAF-1 expression by the two tuberous sclerosis gene products.
    Hengstschläger M; Rosner M; Fountoulakis M; Lubec G
    Biochem Biophys Res Commun; 2003 Aug; 307(3):737-42. PubMed ID: 12893285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberin activates the proapoptotic molecule BAD.
    Freilinger A; Rosner M; Krupitza G; Nishino M; Lubec G; Korsmeyer SJ; Hengstschläger M
    Oncogene; 2006 Oct; 25(49):6467-79. PubMed ID: 16702951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyst-like tubers are associated with TSC2 and epilepsy in tuberous sclerosis complex.
    Chu-Shore CJ; Major P; Montenegro M; Thiele E
    Neurology; 2009 Mar; 72(13):1165-9. PubMed ID: 19332694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations.
    Jansen FE; Braams O; Vincken KL; Algra A; Anbeek P; Jennekens-Schinkel A; Halley D; Zonnenberg BA; van den Ouweland A; van Huffelen AC; van Nieuwenhuizen O; Nellist M
    Neurology; 2008 Mar; 70(12):908-15. PubMed ID: 18032745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression profiling in tuberous sclerosis complex (TSC) knockout mouse astrocytes to characterize human TSC brain pathology.
    Ess KC; Uhlmann EJ; Li W; Li H; Declue JE; Crino PB; Gutmann DH
    Glia; 2004 Apr; 46(1):28-40. PubMed ID: 14999811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tuberous sclerosis complex].
    Brandt-Hansen P; Solhoff R
    Tidsskr Nor Laegeforen; 2007 Mar; 127(7):870-3. PubMed ID: 17435807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of epilepsy in tuberous sclerosis complex.
    Curatolo P; D'Argenzio L; Cerminara C; Bombardieri R
    Expert Rev Neurother; 2008 Mar; 8(3):457-67. PubMed ID: 18345974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
    Astrinidis A; Henske EP
    Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.